CEO & President
QurCan Therapeutics
QurCan Therapeutics develops proprietary nanoparticle drug delivery technology, known as TERP, to enhance the efficacy of gene chemotherapy by enabling selective tissue targeting and reducing immunogenicity. The technology specifically addresses the challenges of high liver accumulation and toxicity associated with existing nanoparticle systems, particularly for treating cancer and central nervous system diseases.
- Biotechnology
Updated 23 months ago
Funding
Raised to date
$4.8MRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Funding rounds are not available yet.
Founders
Product
Problem
Existing nanoparticle drug delivery systems often suffer from high liver accumulation and toxicity, limiting their efficacy, especially in treating cancer and central nervous system (CNS) diseases. These systems can also trigger immunogenic responses, further hindering their therapeutic potential.
Solution
QurCan Therapeutics is developing a proprietary nanoparticle drug delivery technology called TERP to overcome the limitations of existing systems. TERP enables selective tissue targeting, particularly to the brain and spleen, while minimizing immunogenicity and reducing liver accumulation. This targeted delivery enhances the efficacy of gene therapies and other biological therapeutics, offering improved treatment options for cancer and CNS diseases.
Target Audience
The primary target audience includes researchers and pharmaceutical companies focused on developing advanced nanomedicines for cancer and central nervous system diseases.
Features
- TERP technology facilitates non-immunogenic delivery of nucleotides and other biological molecules.
- Selective tissue targeting capabilities, with a focus on the brain and spleen.
- Designed to minimize liver accumulation and toxicity associated with traditional nanoparticle systems.
- Applicable to a range of therapeutic modalities, including gene therapy and nanomedicines.